Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (47)
  • Open Access

    ARTICLE

    AGPAT3 Regulates Immune Microenvironment in Osteosarcoma via Lysophosphatidic Acid Metabolism

    Shenghui Su, Yu Zeng, Jiaxin Chen, Xieping Dong*

    Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070558 - 30 December 2025

    Abstract Background: Recent studies have shown glycerolipid metabolism played an essential role in multiple tumors, however, its function in osteosarcoma is unclear. This study aimed to explore the role of glycerolipid metabolism in osteosarcoma. Methods: We conducted bioinformatics analysis using data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database and single-cell RNA sequencing. Least Absolute Shrinkage and Selection Operator (LASSO) regression was used to identify the Glycerolipid metabolism-related genes associated with the clinical outcome of osteosarcoma. Tumor-associated macrophages (TAMs) and their interactions with immune cells were examined through single-cell analysis and co-culture experiments.… More >

  • Open Access

    COMMENTARY

    CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge

    Xuejun Guo1,2, Yilin Fu3, Natalia Baran4,5, Wenxue Ma6,*

    Oncology Research, Vol.33, No.11, pp. 3375-3385, 2025, DOI:10.32604/or.2025.071708 - 22 October 2025

    Abstract Cluster of differentiation 47 (CD47), an immune checkpoint commonly referred to as the “don’t eat me” signal, plays a pivotal role in tumor immune evasion by inhibiting phagocytosis through interaction with signal regulatory protein alpha (SIRPα) on macrophages and dendritic cells (DCs). Although early enthusiasm drove broad clinical development, recent discontinuations of major CD47-targeted programs have prompted re-evaluation of its therapeutic potential. The purpose of this commentary is to contextualize the setbacks observed with first-generation CD47 inhibitors and to highlight strategies aimed at overcoming their limitations. Clinical challenges, including anemia, thrombocytopenia, suboptimal pharmacokinetics, and limited… More >

  • Open Access

    ARTICLE

    Inhibition of Proteasome LMP2 Activity Suppresses Chil3 Expression in Mouse Colon Adenocarcinoma Tissue and Restrains Tumor Growth

    Tatiana M. Astakhova, Nikita S. Karpov, Nataliya O. Dashenkova, Elena V. Alpeeva, Mikhail V. Nesterchuk, Sergey B. Akopov, Arsen S. Mikaelyan, Anfisa S. Ryabchenko, Pavel A. Erokhov, Natalia P. Sharova*

    Oncology Research, Vol.33, No.9, pp. 2573-2595, 2025, DOI:10.32604/or.2025.066611 - 28 August 2025

    Abstract Objectives: Proteasomes, multi-subunit proteases, are key actors of cellular protein catabolism and a number of regulatory processes. The detection of subtle proteasome functioning in tumors may contribute to our understanding of the mechanisms of cancer development. The current study aimed to identify the role of low molecular mass protein 2 (LMP2), a proteasome immune subunit, in the development of mouse colon 26 (C26) adenocarcinoma. Methods: The functions of the LMP2 subunit in tumor development in Balb/c mice were studied using its irreversible inhibitor KZR-504. LMP2 activity was detected by the hydrolysis of the fluorogenic substrate… More >

  • Open Access

    REVIEW

    Targeting TAMs & CAFs in melanoma: New approaches to tumor microenvironment therapy

    Yuriy Mayasin1, Maria Osinnikova1, Daria Osadchaya1, Victoria Dmitrienko1, Anna Gorodilova1, Chulpan Kharisova1, Kristina Kitaeva1, Ivan Filin1, Valeria Solovyeva1, Albert Rizvanov1,2,*

    Oncology Research, Vol.33, No.9, pp. 2221-2242, 2025, DOI:10.32604/or.2025.064677 - 28 August 2025

    Abstract Melanoma is a malignant neoplasm with a high propensity to metastasize, arising from melanocytes and contributing significantly to global morbidity and mortality. Despite the demonstrated efficacy of many immunotherapy approaches, these methods rely on direct destruction of tumor cells with minimal impact on the aggregate of nearby non-tumor cells, the extracellular matrix, and blood vessels that form the tumor microenvironment (TME). The TME is known to be heterogeneous and dynamic, exerting both antitumor and pro-tumor effects depending on the specific features and stage of carcinogenesis. TME has been shown in several studies to promote… More >

  • Open Access

    REVIEW

    Plasticity of myeloid-derived suppressor cells in cancer and cancer therapy

    JIAJIA LV, XIAOYOU ZHONG, LIN WANG, WEIFEI FAN*

    Oncology Research, Vol.33, No.7, pp. 1581-1592, 2025, DOI:10.32604/or.2025.060063 - 26 June 2025

    Abstract The tumor microenvironment (TME) is a complex and dynamic network comprised of tumor cells, surrounding cellular components, various signaling molecules, and the stroma. Myeloid-derived suppressor cells (MDSCs) are pivotal players in the immunosuppressive landscape of the TME, effectively hindering antitumor immune responses and facilitating tumor progression. Originating from pathologically activated myeloid precursors and relatively immature myeloid cells, MDSCs retain plasticity to further differentiate into other myeloid cells, such as macrophages or dendritic cells, which underpins their heterogeneity and adaptability in response to the TME. In this review, we delve into the plasticity of MDSCs in More >

  • Open Access

    REVIEW

    Molecular insights into immune evasion in head and neck squamous cell carcinomas: Toward a promising treatment strategy

    HYEON JI KIM1,#, BO KYUNG JOO1,#, JIN-SEOK BYUN2,3,*, DO-YEON KIM1,3,*

    Oncology Research, Vol.33, No.6, pp. 1271-1282, 2025, DOI:10.32604/or.2025.062207 - 29 May 2025

    Abstract Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive and devastating disease arising primarily from the mucosal epithelium of the oral cavity, pharynx, and larynx. HNSCC ranks as the sixth most common cancer worldwide, carrying significant morbidity and mortality. HPV-positive HNSCC can be partially prevented with the FDA-approved HPV vaccine and generally exhibits a more favorable prognosis compared to HPV-negative cases. However, effective screening and treatment approaches remain elusive for HPV-negative HNSCC. While precancerous lesions may precede invasive cancer in certain situations, most patients present with advanced disease without prior indication of precancerous More >

  • Open Access

    REVIEW

    Decoding CD24: Roles of chemoradiotherapy resistance and potential as therapeutic targets

    YU HONG1,#, YUNXIANG TANG1,#, WENYAN ZHOU1, HANYUE LUO2, LINLIN BU2, HUI QIU3,*, QIUJI WU3,*

    Oncology Research, Vol.33, No.6, pp. 1347-1361, 2025, DOI:10.32604/or.2025.059327 - 29 May 2025

    Abstract As a rising immune checkpoint on tumor cells, CD24 is closely related to tumorigenesis and progression. CD24 can directly regulate the malignant behavior of tumor cells and indirectly inhibit the function of immune cells in the meantime, which promotes the immune escape of tumor cells, induces cancer invasion and causes poor prognosis. The basic principle of cancer treatment is to induce cell death and inhibit cell survival. Resistance to chemoradiotherapy is a critical challenge in oncology, which limits the effectiveness of anti-cancer treatments. Many studies have shown a strong association between CD24 and chemoradiotherapy More >

  • Open Access

    ARTICLE

    Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells

    CHENXIAO QIAO1, YIPENG XU2, YEDIE HE2, ZHIJIAN CAI1,*, HUA WANG2,*

    Oncology Research, Vol.33, No.5, pp. 1161-1172, 2025, DOI:10.32604/or.2024.055746 - 18 April 2025

    Abstract Objective: To investigate the anti-tumor effects of an E1B55KD-deleted oncolytic adenovirus, H101, in combination with a humanized anti-PD-1 (Programmed cell death protein 1) monoclonal antibody, Camrelizumab. Methods: Anti-tumor efficacy of intratumoral injection of H101 or/and intraperitoneal injection of Camrelizumab were evaluated in an immune system humanized NOD Prkdcscid Il2rg-/- mice subcutaneous (S.C.) tumor model, established with human glioblastoma of unknown origin cell line U87-MG, and human bladder cancer cell line T24 and YTS-1. The mechanism by which H101 induced anti-tumor immunity were also investigated. Results: Combining H101 with Camrelizumab demonstrated more potent anti-tumor effects than monotherapy in… More >

  • Open Access

    ARTICLE

    Microglia and brain macrophages are differentially associated with tumor necrosis in glioblastoma: A link to tumor progression

    CHRISTINA LOH1, YUQI ZHENG1, ISLAM ALZOUBI2, KIMBERLEY L. ALEXANDER3,4, MAGGIE LEE4, WEI-DONG CAI2, YANG SONG5, KERRIE MCDONALD6, ANNA K. NOWAK7, RICHARD B. BANATI8,9, MANUEL B. GRAEBER1,4,10,*

    Oncology Research, Vol.33, No.4, pp. 937-950, 2025, DOI:10.32604/or.2024.056436 - 19 March 2025

    Abstract Background: Microglia and brain macrophages contribute significantly to the tumor microenvironment in highly malignant glioblastoma where they are considered important drivers of tumor progression. A better understanding of the role of the brain macrophages present in glioblastoma appears crucial for improving therapeutic outcomes, especially in the context of novel immunotherapeutic approaches. Methods: We investigated the regulation of two well-established markers for microglia and brain macrophages, IBA1 and CD163, in relation to glioblastoma tumor necrosis using immunohistochemistry and modality fusion heatmaps of whole slide images obtained from adjacent tissue sections. Results: IBA1 and CD163 showed remarkable differences… More >

  • Open Access

    REVIEW

    Macrophage polarization in cardiac transplantation: Insights into immune modulation and therapeutic approaches

    JINGWEI JIANG1,2, BO JIA3, CHUAN WANG3, CHEN FANG1, YUGUI LI1, GUOXING LING1, BAOSHI ZHENG1,*, CHENG LUO1,*

    BIOCELL, Vol.49, No.1, pp. 61-78, 2025, DOI:10.32604/biocell.2024.056981 - 24 January 2025

    Abstract The role and regulatory mechanisms of macrophage polarization in cardiac transplantation have gained significant attention. Macrophages can polarize into either the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype in response to environmental cues. M1 macrophages facilitate transplant rejection by releasing inflammatory mediators and activating T cells, whereas M2 macrophages support graft survival by secreting anti-inflammatory factors and promoting tissue repair. Mitochondrial quality control regulation plays a crucial role in macrophage polarization, which may influence graft survival and immune responses. This review provides an overview of the current understanding of mitochondrial quality control-regulated macrophage polarization in cardiac More >

Displaying 1-10 on page 1 of 47. Per Page